BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

[1]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[2]  M. Raffeld,et al.  Modeling Tumor-Host Interactions of Chronic Lymphocytic Leukemia in Xenografted Mice to Study Tumor Biology and Evaluate Targeted Therapy , 2013, Leukemia.

[3]  Peter Houghton,et al.  A Proposal Regarding Reporting of In Vitro Testing Results , 2013, Clinical Cancer Research.

[4]  J. Byrd,et al.  Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Deng,et al.  New Strategies in the Treatment of Mantle Cell Lymphoma , 2012, Clinical Cancer Research.

[6]  C. Geest,et al.  The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.

[7]  N. Chiorazzi,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. , 2012, Blood.

[8]  Y Lynn Wang,et al.  SYK inhibition and response prediction in diffuse large B-cell lymphoma. , 2011, Blood.

[9]  M. Keating,et al.  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. , 2011, Blood.

[10]  Jeffrey A Jones,et al.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.

[11]  J. Byrd,et al.  Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Ulrich,et al.  Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Michie,et al.  Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro‐survival microenvironmental signals , 2011, British journal of haematology.

[14]  A. LaCasce,et al.  Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia , 2011, Clinical Cancer Research.

[15]  R. Ulrich,et al.  CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. , 2011, Blood.

[16]  Richard Sherry,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[17]  G. Leone,et al.  The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. , 2010, Blood.

[18]  N. Schmitz,et al.  CNS Disease In Younger Patients ( , 2010 .

[19]  Jeffrey A Jones,et al.  Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals , 2010 .

[20]  K. Anderson,et al.  PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. , 2010, Blood.

[21]  H. M. de Paula,et al.  Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia , 2010, Acta Haematologica.

[22]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[23]  Ronald Levy,et al.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.

[24]  Yoshihiro Baba,et al.  B cell signaling and fate decision. , 2010, Annual review of immunology.

[25]  Facundo D Batista,et al.  Early events in B cell activation. , 2010, Annual review of immunology.

[26]  J. Leonard,et al.  Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib , 2010, Clinical Cancer Research.

[27]  N. Chiorazzi,et al.  In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. , 2009, Blood.

[28]  S. Stilgenbauer,et al.  Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. , 2009, Blood.

[29]  Z. Estrov,et al.  Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. , 2009, Blood.

[30]  G Brockhoff,et al.  Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles , 2009, Leukemia.

[31]  M. Keating,et al.  B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. , 2009, Blood.

[32]  G. Leone,et al.  Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells , 2009, Leukemia.

[33]  E. Cesarman,et al.  Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma , 2009, Leukemia.

[34]  P. Ghia,et al.  Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Hallek,et al.  The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. , 2008, Blood.

[36]  J. Leonard,et al.  Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib , 2008, Leukemia.

[37]  Stefano Monti,et al.  SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. , 2008, Blood.

[38]  Luca Laurenti,et al.  The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. , 2008, Blood.

[39]  N. Chiorazzi,et al.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. , 2007, Blood.

[40]  Jonathan M Irish,et al.  Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. , 2006, Blood.

[41]  Ralf Küppers,et al.  Mechanisms of B-cell lymphoma pathogenesis , 2005, Nature Reviews Cancer.

[42]  Marc K Hellerstein,et al.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. , 2005, The Journal of clinical investigation.

[43]  J. Gribben,et al.  Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. , 2004, Blood.

[44]  J. D. Dal Porto,et al.  B cell antigen receptor signaling 101. , 2004, Molecular immunology.

[45]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[46]  R. Advani,et al.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Gibson,et al.  Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. , 2008, British journal of haematology.